Cargando…

Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy

PURPOSE: We propose and simulate a model-based methodology to incorporate heterogeneous treatment benefit of proton therapy (PrT) versus photon therapy into randomized trial designs. We use radiation-induced pneumonitis (RP) as an exemplar. The aim is to obtain an unbiased estimate of how predicted...

Descripción completa

Detalles Bibliográficos
Autores principales: Scherman, Jonas, Appelt, Ane L., Yu, Jen, Persson, Gitte Fredberg, Nygård, Lotte, Langendijk, Johannes A., Bentzen, Søren M., Vogelius, Ivan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Particle Therapy Co-operative Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874185/
https://www.ncbi.nlm.nih.gov/pubmed/31788505
http://dx.doi.org/10.14338/IJPT-18-00038.1
_version_ 1783472793651773440
author Scherman, Jonas
Appelt, Ane L.
Yu, Jen
Persson, Gitte Fredberg
Nygård, Lotte
Langendijk, Johannes A.
Bentzen, Søren M.
Vogelius, Ivan R.
author_facet Scherman, Jonas
Appelt, Ane L.
Yu, Jen
Persson, Gitte Fredberg
Nygård, Lotte
Langendijk, Johannes A.
Bentzen, Søren M.
Vogelius, Ivan R.
author_sort Scherman, Jonas
collection PubMed
description PURPOSE: We propose and simulate a model-based methodology to incorporate heterogeneous treatment benefit of proton therapy (PrT) versus photon therapy into randomized trial designs. We use radiation-induced pneumonitis (RP) as an exemplar. The aim is to obtain an unbiased estimate of how predicted difference in normal tissue complications probability (ΔNTCP) converts into clinical outcome on the patient level. MATERIALS AND METHODS: ΔNTCP data from in silico treatment plans for photon therapy and PrT for patients with locally advanced lung cancer as well as randomly sampled clinical risk factors were included in simulations of trial outcomes. The model used at point of analysis of the trials was an iQUANTEC model. Trial outcomes were examined with Cox proportional hazards models, both in case of a correctly specified model and in a scenario where there is discrepancy between the dose metric used for ΔNTCP and the dose metric associated with the “true” clinical outcome, that is, when the model is misspecified. We investigated how outcomes from such a randomized trial may feed into a model-based estimate of the patient-level benefit from PrT, by creating patient-specific predicted benefit probability distributions. RESULTS: Simulated trials showed benefit in accordance with that expected when the NTCP model was equal to the model for simulating outcome. When the model was misspecified, the benefit changed and we observed a reversal when the driver of outcome was high-dose dependent while the NTCP model was mean-dose dependent. By converting trial results into probability distributions, we demonstrated large heterogeneity in predicted benefit, and provided a randomized measure of the precision of individual benefit estimates. CONCLUSIONS: The design allows for quantifying the benefit of PrT referral, based on the combination of NTCP models, clinical risk factors, and traditional randomization. A misspecified model can be detected through a lower-than-expected hazard ratio per predicted ΔNTCP.
format Online
Article
Text
id pubmed-6874185
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Particle Therapy Co-operative Group
record_format MEDLINE/PubMed
spelling pubmed-68741852019-12-01 Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy Scherman, Jonas Appelt, Ane L. Yu, Jen Persson, Gitte Fredberg Nygård, Lotte Langendijk, Johannes A. Bentzen, Søren M. Vogelius, Ivan R. Int J Part Ther Original Articles PURPOSE: We propose and simulate a model-based methodology to incorporate heterogeneous treatment benefit of proton therapy (PrT) versus photon therapy into randomized trial designs. We use radiation-induced pneumonitis (RP) as an exemplar. The aim is to obtain an unbiased estimate of how predicted difference in normal tissue complications probability (ΔNTCP) converts into clinical outcome on the patient level. MATERIALS AND METHODS: ΔNTCP data from in silico treatment plans for photon therapy and PrT for patients with locally advanced lung cancer as well as randomly sampled clinical risk factors were included in simulations of trial outcomes. The model used at point of analysis of the trials was an iQUANTEC model. Trial outcomes were examined with Cox proportional hazards models, both in case of a correctly specified model and in a scenario where there is discrepancy between the dose metric used for ΔNTCP and the dose metric associated with the “true” clinical outcome, that is, when the model is misspecified. We investigated how outcomes from such a randomized trial may feed into a model-based estimate of the patient-level benefit from PrT, by creating patient-specific predicted benefit probability distributions. RESULTS: Simulated trials showed benefit in accordance with that expected when the NTCP model was equal to the model for simulating outcome. When the model was misspecified, the benefit changed and we observed a reversal when the driver of outcome was high-dose dependent while the NTCP model was mean-dose dependent. By converting trial results into probability distributions, we demonstrated large heterogeneity in predicted benefit, and provided a randomized measure of the precision of individual benefit estimates. CONCLUSIONS: The design allows for quantifying the benefit of PrT referral, based on the combination of NTCP models, clinical risk factors, and traditional randomization. A misspecified model can be detected through a lower-than-expected hazard ratio per predicted ΔNTCP. The Particle Therapy Co-operative Group 2019-03-21 2019 /pmc/articles/PMC6874185/ /pubmed/31788505 http://dx.doi.org/10.14338/IJPT-18-00038.1 Text en © Copyright 2019 International Journal of Particle Therapy http://creativecommons.org/licenses/by/3.0/ Distributed under Creative Commons CC-BY
spellingShingle Original Articles
Scherman, Jonas
Appelt, Ane L.
Yu, Jen
Persson, Gitte Fredberg
Nygård, Lotte
Langendijk, Johannes A.
Bentzen, Søren M.
Vogelius, Ivan R.
Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy
title Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy
title_full Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy
title_fullStr Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy
title_full_unstemmed Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy
title_short Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy
title_sort incorporating ntcp into randomized trials of proton versus photon therapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874185/
https://www.ncbi.nlm.nih.gov/pubmed/31788505
http://dx.doi.org/10.14338/IJPT-18-00038.1
work_keys_str_mv AT schermanjonas incorporatingntcpintorandomizedtrialsofprotonversusphotontherapy
AT appeltanel incorporatingntcpintorandomizedtrialsofprotonversusphotontherapy
AT yujen incorporatingntcpintorandomizedtrialsofprotonversusphotontherapy
AT perssongittefredberg incorporatingntcpintorandomizedtrialsofprotonversusphotontherapy
AT nygardlotte incorporatingntcpintorandomizedtrialsofprotonversusphotontherapy
AT langendijkjohannesa incorporatingntcpintorandomizedtrialsofprotonversusphotontherapy
AT bentzensørenm incorporatingntcpintorandomizedtrialsofprotonversusphotontherapy
AT vogeliusivanr incorporatingntcpintorandomizedtrialsofprotonversusphotontherapy